LUCID CAPITAL MARKETS Initiates Coverage On NextCure with Buy Rating, Announces Price Target of $25

LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on NextCure (NASDAQ:NXTC) with a Buy rating and announces Price Target of $25.